.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The U.S. Food and Drug Administration (FDA) has cleared the first OTC glucose monitor for pediatric use. Specifically, the regulatory agency expanded the authorization of Dexcom's Stelo Glucose Biosensor System. Consequently, the device is now available for children aged two years and older who do not use insulin. Previously, the FDA approved Stelo only for adults aged 18 and older in March 2024. Therefore, this decision marks a significant milestone in accessible pediatric healthcare.
The Stelo system uses a wearable sensor and a smartphone app to measure glucose levels. Furthermore, the device updates readings and tracks trends every 15 minutes. Each sensor lasts up to 15 days under normal conditions. However, the FDA noted that sensor wear time may be shorter in children due to physiological and behavioral reasons. Consequently, parents must monitor the adhesive and placement of the sensor regularly.
This device helps children and their caregivers understand how lifestyle choices affect blood sugar. Specifically, it reveals the immediate impacts of meals, exercise, and daily routines. Importantly, pediatric patients must use this device under direct adult supervision. Healthcare providers should advise parents to consult a professional before altering any medications. Moreover, the device is not suitable for individuals with problematic low blood sugar because it lacks hypoglycemia alerts.
Q1: Who is eligible to use the pediatric Dexcom Stelo system?
The device is cleared for children aged two years and older who do not use insulin.
Q2: Does the Stelo glucose monitor alert users about low blood sugar?
No. The device does not alert users about problematic low blood sugar.
Q3: How long does each Stelo sensor last?
Each sensor lasts up to 15 days. However, pediatric wear time may be shorter.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The FDA has cleared Dexcom's Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for pediatric use. The device is approved for children aged two and older who do not use insulin, helping caregivers track real-time glucose trends.
2 months ago
A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
